NeuroGenesis Awarded Grant from National MS Society’s Fast Forward Program to Advance Cell Therapy & Phase IIb Trial
Summary
Nir Netzer, COO of NeuroGenesis, emphasized the significance of the grant, stating, This funding helps refine our patient selection methodology, improving predictive capabilities. With cutting-edge proteomics, we aim to increase trial success rates and ensure NG01 reaches patients who need it most.There is a critical unmet need for therapies that focus on repairing myelin and restoring function to people with secondary progressive multiple sclerosis, says Walter Kostich, PhD, Associate Vice President, Translational Research at the National MS Society. Learn more at nationalmssociety.org.About NG01 Cellular TherapyNG01 is a unique population of autologous bone marrow-derived stem cells engineered to secrete high levels of remyelinating and neurotrophic factors directly at injury sites in the central nervous system. Over nine months, patients will receive four intrathecal NG01 injections, with results anticipated in early 2028.About NeuroGenesisNeuroGenesis is a privately held clinical-stage company developing cell-based therapies for neurodegenerative diseases. Its cellular therapy platform delivers high concentrations of neuroprotective, neurotrophic, and anti-inflammatory proteins directly to damaged brain regions.NG01, the companys lead product, has received FDA clearance for a global Phase IIb placebo-controlled trial for SPMS patients.